Akadeum Life Sciences Announces Instrument-Free, Large-Scale Microbubble Workflow for Cell Therapy Manufacturing

ANN ARBOR, Mich., June 24, 2025 /PRNewswire/ -- Akadeum Life Sciences, the world leader in advanced cell separation technology, proudly announces a groundbreaking workflow that leverages its proprietary microbubble platform to enable instrument-free, large-scale cell isolation for cell therapy manufacturing. This innovative solution empowers researchers and manufacturers to efficiently isolate target cells directly in processing bags, eliminating the need for complex instrumentation and streamlining the cell therapy workflow to truly enable decentralized and point-of-care manufacturing models, reduce costs typical of complex cell therapy workflows such as GMP suite time, labor and training, and enable more broad access to life saving therapies.

Key Features and Benefits

• No-Instrument Workflow: Akadeum's microbubble technology eliminates equipment costs (reduction in therapeutic footprint), reduces GMP suite time by up to 80% and solves the challenge of training technicians on complex processes and equipment, with a simple, gentle and efficient cell isolation that can be done at point-of-care locations.
• In-Bag, Large-Scale Isolation: The platform supports cell isolation up to 50 billion cells directly within both sterile processing bags and fresh collected apheresis material, enabling pre-clinical through commercial scale with closed-system operations and the same reagents at each stage of development. This approach eliminates the need for traditional cell washing and isolation specific instrumentation, minimizing cell handling steps and reducing the complexity of cell therapy manufacturing.
• Sterile Tube Welding Integration: Following isolation, the closed bag containing enriched cells can be seamlessly welded via sterile tube connection to a ScaleReady G-Rex® flask or other expansion vessel or bag, maintaining sterility and process continuity for downstream cell expansion and activation.
• Flexible for Existing Workflows: The workflow is adaptable for a variety of cell types and therapy applications, supporting both research and GMP-compliant manufacturing environments and is driving companies to amend existing INDs to realize the cost and time benefits of a microbubble-based workflow.

Solving Cell Therapy Manufacturing Complexities for Greater Access

Akadeum's microbubble-based cell isolation workflow addresses critical bottlenecks in cell therapy manufacturing by providing a scalable, gentle, and fully closed GMP solution for cell separation. This approach accelerates development, enhances cell viability, and supports the production of high-quality cell therapy products in a timely, cost-effective manner.

"A workflow that is instrument free enables more rapid growth of cell therapy manufacturing, lessening the supply chain demands and reducing costs, while increasing accessibility via decentralized manufacturing models. We are excited to provide our microbubble technology for large-scale cell isolation in a manner that is both efficient and GMP compliant," said Brandon McNaughton, Ph.D., CEO of Akadeum Life Sciences. "Our microbubble technology is setting a new standard for cell therapy manufacturing workflows."

Akadeum is a partner in the ScaleReady G-Rex® Grant Program. Recipients of the grant may reach out to Akadeum for grant-specific discounting on the cell therapy product line.

About Akadeum Life Sciences

Akadeum Life Sciences is dedicated to advancing cell separation technology through its unique buoyant microbubble platform, enabling researchers and manufacturers to achieve higher yields, better purity, and improved process simplicity across a range of life science applications. Our mission is to create separation technologies to advance human health. We envision a world where innovative separations empower researchers and clinicians to unlock breakthroughs in diagnostics, therapeutics, and basic research.

For more information, visit www.akadeum.com or attend the webinar Thursday June 26, 2025.

Media Contact: Brandon McNaughton, [email protected] 

SOURCE Akadeum Life Sciences Inc